Angiodynamic Inc
ANGOHealthcare·Medical Instruments & Supplies·USA·Small·NASD·Nov 11 • 3:59 PM ET
12.42+0.35 (2.90%)
2026-11-12 04:34 CET
Market cap
522.32 USD m
Revenue, TTM
325.38 USD m
Net income, TTM
-32.94 USD m
Free cash flow, TTM
-3.87 USD m
EPS diluted, TTM
-0.79
P/E
-
Price
ANGO against its 20, 50 and 200-day averages2050200beatmiss
23.8% under the 52-week high of 16.29 on 19 Aug 2026. 52-week low 9.39 on 7 Apr 2026. Last 15 sessions, 10.5% high to low
Volume 0.68× normal · the line is the 50-bar volume average
Profile
ANGO52-week range, 44% of the way up
9.3916.29
AngioDynamics, Inc. is a medical device company, which engages in the development, manufacturing, and sale of medical devices for vascular access, surgery, peripheral vascular disease, and oncology. The firm offers ablation systems, fluid management systems, vascular access, angiographic, drainage, thrombolytic, and venous products. It operates through the Med Tech and Med Device segments. The Med Tech segment consists of technology portfolio including Auryon, the thrombus management platform and NanoKnife. The Med Device segment focuses on core, venous, ports, and other oncology products. The company was founded by Howard S. Stern and Eamonn P. Hobbs on February 9, 1988 and is headquartered in Latham, NY.
| Index | RUT |
|---|---|
| Employees | 632 |
| IPO | May 27, 2004 |
| Beta | 0.28 |
| ATR, 14d | 0.57 |
| Rel volume | 0.68 |
| Short float | 5.38% |
| Insider own | 11.52% |
| Inst own | 88.49% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | 522.32M |
| Enterprise Value | 499.09M |
| Income | -32.94M |
| Sales | 325.38M |
| Book/sh | 3.86 |
| Cash/sh | 0.81 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 632 |
| IPO | May 27, 2004 |
Ratios
| P/E | - |
|---|---|
| Forward P/E | - |
| PEG | - |
| P/S | 1.61 |
| P/B | 3.21 |
| P/C | 15.38 |
| P/FCF | - |
| EV/EBITDA | 173.29 |
| EV/Sales | 1.53 |
| Quick Ratio | 1.48 |
| Current Ratio | 2.40 |
| Debt/Eq | 0.07 |
| LT Debt/Eq | 0.05 |
| Option/Short | Yes / Yes |
Earnings
| EPS (ttm) | -0.79 |
|---|---|
| EPS next Y | -0.10 |
| EPS next Q | -0.07 |
| EPS this Y | -82.03% |
| EPS next Y | 61.55% |
| EPS next 5Y | - |
| EPS past 3/5Y | 12.67% -1.46% |
| Sales past 3/5Y | -1.86% 1.93% |
| EPS Y/Y TTM | -0.88% |
| Sales Y/Y TTM | 8.20% |
| EPS Q/Q | 36.22% |
| Sales Q/Q | 6.87% |
| Earnings | Oct 08 BMO |
| EPS/Sales Surpr. | 64.44% 0.50% |
Ownership
| Insider Own | 11.52% |
|---|---|
| Insider Trans | -1.00% |
| Inst Own | 88.49% |
| Inst Trans | -2.38% |
| ROA | -12.98% |
| ROE | -19.21% |
| ROIC | -19.05% |
| Gross Margin | 52.34% |
| Oper. Margin | -6.01% |
| Profit Margin | -10.12% |
| SMA20 | 3.90% |
| SMA50 | -8.44% |
| SMA200 | -0.92% |
| Trades | - |
Technical
| Shs Outstand | 42.42M |
|---|---|
| Shs Float | 37.21M |
| Short Float | 5.38% |
| Short Ratio | 3.08 |
| Short Interest | 2.00M |
| 52W High | 16.29 -23.76% |
| 52W Low | 9.39 32.27% |
| Volatility | 4.04% 4.42% |
| ATR (14) | 0.57 |
| RSI (14) | 49.47 |
| Beta | 0.28 |
| Rel Volume | 0.68 |
| Avg Volume | 650.57K |
| Volume | 441,416 |
Performance
| Perf Week | 1.39% |
|---|---|
| Perf Month | 13.94% |
| Perf Quarter | -20.69% |
| Perf Half Y | 14.58% |
| Perf YTD | -3.27% |
| Perf Year | -1.51% |
| Perf 3Y | 100.00% |
| Perf 5Y | -57.98% |
| Perf 10Y | -26.51% |
| Recom | 1.00 |
| Target Price | 18.33 |
| Prev Close | 12.07 |
| Price | 12.42 |
| Change % | 2.90% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Jul 16, 2025 | Initiated | LLake Street | Buy | $24 | +93.2% |
| Apr 05, 2024 | Upgrade | OOppenheimer | Perform → Outperform | $12 | -3.4% |
| Sep 25, 2023 | Initiated | HH.C. Wainwright | Buy | $19 | +53.0% |
| Apr 17, 2023 | Downgrade | RRaymond James | Strong Buy → Outperform | $14 → $13 | +4.7% |
| Oct 15, 2021 | Upgrade | CCanaccord Genuity | Hold → Buy | $28 → $37 | +197.9% |
| Aug 20, 2021 | Initiated | OOppenheimer | Perform | ||
| Nov 25, 2020 | Upgrade | RRaymond James | Mkt Perform → Strong Buy | $18 | +44.9% |
| Apr 08, 2020 | Downgrade | KKeyBanc Capital Markets | Overweight → Sector Weight | ||
| Apr 01, 2019 | Upgrade | KKeyBanc Capital Markets | Sector Weight → Overweight | ||
| Apr 03, 2018 | Upgrade | RRaymond James | Mkt Perform → Outperform |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| MMSI | Merit Medical Systems Inc | 5.28B |
| LMAT | Lemaitre Vascular Inc | 1.81B |
| TFX | Teleflex Incorporated | 6.20B |
| PEN | Penumbra Inc | 12.68B |
| BDX | Becton Dickinson & Co | 58.43B |
| BSX | Boston Scientific Corp | 65.41B |
| ICUI | ICU Medical Inc | 4.46B |
| ATRC | Atricure Inc | 2.93B |
| PROF | Profound Medical Corp | 287.55M |
| ITGR | Integer Holdings Corp | 4.31B |
Insider trading
10 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Trowbridge Stephen A | EVP and CFO | Oct 29 '26 | Sale | 12.27 | 23,615 | 289,756 | 280,461 | Oct 30 04:15 PM |
| Trowbridge Stephen A | EVP and CFO | Oct 28 '26 | Sale | 12.17 | 1,720 | 20,932 | 304,076 | Oct 30 04:15 PM |
| STEPHEN TROWBRIDGE | Officer | Oct 29 '26 | Proposed Sale | 12.27 | 23,615 | 289,722 | Oct 29 04:02 PM | |
| Nighan Warren JR | SVP Quality and Regulatory | Jul 30 '26 | Sale | 14.72 | 23,370 | 344,006 | 64,745 | Jul 31 04:45 PM |
| WARREN NIGHAN | Officer | Jul 30 '26 | Proposed Sale | 14.72 | 23,370 | 344,004 | Jul 30 06:02 PM | |
| Piccinini Laura | SVP International | Jul 22 '26 | Option Exercise | 0.00 | 8,047 | 0 | 86,435 | Jul 24 06:10 PM |
| Nighan Warren JR | SVP Quality and Regulatory | Jul 22 '26 | Option Exercise | 0.00 | 5,694 | 0 | 89,786 | Jul 24 06:10 PM |
| Trowbridge Stephen A | EVP and CFO | Jul 22 '26 | Option Exercise | 0.00 | 16,296 | 0 | 314,115 | Jul 24 06:10 PM |
| Clemmer James C | President and CEO | Jul 22 '26 | Option Exercise | 0.00 | 52,358 | 0 | 889,176 | Jul 24 06:10 PM |
| Campbell Chad Thomas | SVP/GM, Vascular Access | Jul 22 '26 | Option Exercise | 0.00 | 6,466 | 0 | 111,006 | Jul 24 06:10 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 687.42B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.38B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.47B |
| DFAS | U.S. Small Cap Portfolio-ETF Class Shares | AUM: 15.51B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.75B |
| IWN | iShares Russell 2000 Value ETF | AUM: 14.10B |
| DFAC | U.S. Core Equity 2 Portfolio-ETF Class Shares | AUM: 49.14B |
| SCHA | Schwab U.S. Small-Cap ETF | AUM: 22.25B |
| IHI | iShares U.S. Medical Devices ETF | AUM: 4.07B |
| DFMC | U.S. Micro Cap Portfolio ETF Class Shares | AUM: 212.10M |
News
latest 14 of 198- AngioDynamics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
- AngioDynamics to Participate in Upcoming Investor Conferences (Business Wire)
- AngioDynamics Announces Publication of DIRECT Study Results and New Category I CPT Code for Pancreatic IRE (Business Wire)
- AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer (Business Wire)
- AngioDynamics Shares Fall 4.3% Despite Q1 Earnings Beat and Strong Med Tech Growth (InvestorsHub) -20.86%
- AngioDynamics stock slips 4% despite beating estimates on Med Tech growth (Investing.com)
- AngioDynamics: Fiscal Q1 Earnings Snapshot (Associated Press)
- AngioDynamics Reports Fiscal Year 2027 First Quarter Financial Results; Continued Execution Drives Med Tech Growth and Profitability (Business Wire)
- AngioDynamics Announces Appointment of Eric Honroth as President and Chief Executive Officer (Business Wire)
- PepsiCo headlines Thursday's earnings slate (MarketWatch)
- Stock Market Today: Dow set for 300-point drop, S&P 500 and Nasdaq to decline as oil prices jump on threat of war resuming in Iran (MarketWatch)
- AngioDynamics and The PERT Consortium Name Jacobi Hospital as ALPHA-PE Research Fund Award Recipient to Advance Real-World Pulmonary Embolism Evidence (Business Wire)
- AngioDynamics to Report Fiscal 2027 First Quarter Results on October 8, 2026 (Business Wire)
- AngioDynamics to Participate in Upcoming Investor Conferences (Business Wire)
Quarterly earnings
actual against estimate| Period | Reported | EPS act | EPS est | EPS rep | Sales act | Sales est | Analysts |
|---|---|---|---|---|---|---|---|
| 2026Q1 | 2026-10-08 | -0.040 | -0.113 | -0.170 | 80.92 | 80.51 | 3 |
| 2025Q4 | 2026-07-14 | -0.070 | -0.090 | -0.274 | 86.61 | 80.24 | 3 |
| 2025Q3 | 2026-04-02 | 0.020 | -0.110 | -0.194 | 78.42 | 76.77 | 3 |
| 2025Q2 | 2026-01-06 | 0.000 | -0.100 | -0.153 | 79.43 | 76.43 | 3 |
| 2025Q1 | 2025-10-02 | -0.100 | -0.122 | -0.265 | 75.71 | 72.29 | 3 |
| 2024Q4 | 2025-07-15 | -0.030 | -0.119 | -0.148 | 80.16 | 74.26 | 3 |
| 2024Q3 | 2025-04-02 | -0.080 | -0.130 | -0.108 | 72.01 | 70.30 | 3 |
| 2024Q2 | 2025-01-08 | -0.040 | -0.110 | -0.262 | 73.02 | 70.93 | 3 |
| 2024Q1 | 2024-10-03 | -0.110 | -0.147 | -0.315 | 67.49 | 67.93 | 3 |
| 2023Q4 | 2024-07-16 | -0.060 | -0.167 | -0.333 | 71.12 | 70.86 | 3 |
| 2023Q3 | 2024-04-04 | -0.160 | -0.155 | -4.666 | 66.00 | 74.21 | 2 |
| 2023Q2 | 2024-01-05 | -0.050 | -0.074 | -0.722 | 79.07 | 81.16 | 4 |
| 2023Q1 | 2023-10-04 | -0.120 | -0.130 | 1.148 | 78.68 | 77.70 | 4 |
| 2022Q4 | 2023-07-12 | 0.020 | 0.022 | -0.542 | 91.07 | 90.74 | 4 |
| 2022Q3 | 2023-03-30 | -0.030 | -0.008 | -0.240 | 80.71 | 83.20 | 4 |
| 2022Q2 | 2023-01-05 | 0.010 | -0.010 | -0.215 | 85.43 | 84.38 | 4 |
Annual earnings
| Period | EPS act | EPS est | EPS rep | Sales act | Sales est |
|---|---|---|---|---|---|
| 2019FY | 0.090 | 0.093 | -4.394 | 264.16 | 268.37 |
| 2020FY | 0.050 | 0.047 | -0.823 | 291.01 | 286.73 |
| 2021FY | 0.000 | -0.005 | -0.681 | 316.22 | 312.13 |
| 2022FY | -0.060 | -0.056 | -1.328 | 338.75 | 338.4 |
| 2023FY | -0.380 | -0.517 | -4.588 | 270.72 | 270.63 |
| 2024FY | -0.150 | -0.277 | -0.832 | 292.69 | 286.65 |
| 2025FY | -0.150 | -0.162 | -0.880 | 320.17 | 314.12 |
| 2026FY | - | -0.273 | - | - | 337.93 |
| 2027FY | - | -0.105 | - | - | 355.37 |
| 2028FY | - | 0.220 | - | - | 375.4 |
| 2029FY | - | 0.370 | - | - | 397.4 |
| 2030FY | - | 0.420 | - | - | 419.6 |
Estimate revisions
last 14 periods| Period | Type | Date | Estimates | Up | Down | Mean | Low | High |
|---|---|---|---|---|---|---|---|---|
| 2026Q2 | S | 2026-10-22 | 3 | 1 | 0 | 84.32 | 83.00 | 85.40 |
| 2026Q2 | S | 2026-10-13 | 4 | 1 | 0 | 84.27 | 83.00 | 85.40 |
| 2026Q2 | S | 2026-10-12 | 4 | 1 | 0 | 84.28 | 83.00 | 85.40 |
| 2026Q2 | S | 2026-10-08 | 4 | 0 | 0 | 84.03 | 82.00 | 85.40 |
| 2026Q2 | S | 2026-09-27 | 4 | 0 | 0 | 83.98 | 82.00 | 85.00 |
| 2026Q2 | S | 2026-08-11 | 4 | 3 | 0 | 83.98 | 82.00 | 85.00 |
| 2026Q2 | S | 2026-07-14 | 4 | 3 | 0 | 83.98 | 82.00 | 85.00 |
| 2026Q2 | S | 2026-06-16 | 3 | 0 | 0 | 82.03 | 80.50 | 82.80 |
| 2026Q2 | S | 2026-05-12 | 3 | 1 | 0 | 82.03 | 80.50 | 82.80 |
| 2026Q2 | S | 2026-04-02 | 3 | 1 | 0 | 82.03 | 80.50 | 82.80 |
| 2026Q2 | S | 2026-03-22 | 2 | 0 | 0 | 80.90 | 80.50 | 81.30 |
| 2026Q2 | S | 2026-03-01 | 2 | 1 | 0 | 80.90 | 80.50 | 81.30 |
| 2026Q2 | S | 2026-01-06 | 2 | 2 | 0 | 80.90 | 80.50 | 81.30 |
| 2026Q2 | S | 2025-12-16 | 2 | 0 | 0 | 80.04 | 79.50 | 80.57 |
Estimate history
| EPS, annual | 0.441 | 0.409 | -4.394 | -0.823 | -0.681 | -1.328 | -4.588 | -0.832 | -0.885 | -0.7896 |
|---|---|---|---|---|---|---|---|---|---|---|
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| EPS, quarterly | -0.315 | -0.262 | -0.108 | -0.148 | -0.265 | -0.153 | -0.194 | -0.274 | -0.169 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
| Sales, annual | 261.655 | 270.634 | 264.157 | 291.01 | 316.219 | 338.752 | 303.914 | 292.498 | 320.174 | 325.38 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
| Sales, quarterly | 67.491 | 72.845 | 72.004 | 80.158 | 75.711 | 79.433 | 78.423 | 86.607 | 80.915 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
| Shares, annual | 37.224 | 37.614 | 38.079 | 38.551 | 39.171 | 39.611 | 40.432 | 40.994 | 41.7 | 42.424 |
| Period | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | MRQ |
| Shares, quarterly | 41.004 | 40.836 | 40.971 | 40.994 | 41.447 | 41.574 | 41.682 | 41.7 | 42.424 | |
| Period | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
Income statement, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 325.38 | 320.17 | 292.50 | 303.91 | 338.75 | 316.22 | 291.01 | 264.16 | 270.63 |
| Cost of Goods Sold Incl. D&A | 155.06 | 155.96 | 145.11 | 162.26 | 183.30 | 169.94 | 152.36 | 132.01 | 131.69 |
| Gross Profit | 170.32 | 164.21 | 147.39 | 141.65 | 155.46 | 146.27 | 138.65 | 132.15 | 138.94 |
| Selling, General and Administrative Excl. Other | 189.87 | 186.54 | 170.56 | 174.42 | 173.68 | 164.15 | 151.78 | 144.97 | 139.99 |
| Research and Development | 31.01 | 29.45 | 26.22 | 31.51 | 29.88 | 30.74 | 36.39 | 29.68 | 28.26 |
| Other Operating Expense | 0.00 | 0.00 | 0.89 | 1.07 | 0.46 | 0.34 | 1.83 | 1.22 | 0.00 |
| Operating Income | -19.55 | -22.33 | -24.06 | -33.84 | -18.68 | -18.22 | -14.96 | -14.04 | -1.04 |
| Interest Expense | 0.38 | 0.30 | - | - | 2.70 | 0.69 | 0.86 | 0.91 | 5.10 |
| Unusual Expense | 16.47 | 15.92 | 15.89 | 213.09 | 32.50 | 10.25 | 20.32 | 153.06 | 8.35 |
| Net Income Before Taxes | -32.76 | -36.30 | -34.03 | -191.64 | -54.44 | -29.95 | -36.05 | -168.13 | -14.70 |
| Income Taxes | 0.18 | 0.44 | -0.04 | -7.29 | -2.00 | -3.40 | -4.50 | -1.35 | -3.56 |
| Consolidated Net Income | -32.94 | -36.74 | -33.99 | -184.35 | -52.44 | -26.55 | -31.55 | -166.79 | -11.15 |
| Net Income From Continuing Operations | -32.94 | -36.74 | -33.99 | -184.35 | -52.44 | -26.55 | -31.55 | -166.79 | -11.15 |
| Net Income | -32.94 | -36.74 | -33.99 | -184.35 | -52.44 | -26.55 | -31.55 | -166.79 | 15.35 |
| EPS (Recurring) | -0.51 | -0.62 | -0.56 | -0.88 | -0.75 | -0.50 | -0.45 | -1.57 | 0.57 |
| EPS (Basic, Before Extraordinaries) | -0.79 | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 | -0.82 | -4.39 | 0.41 |
| EPS (Diluted) | -0.79 | -0.88 | -0.83 | -4.59 | -1.33 | -0.68 | -0.82 | -4.39 | 0.41 |
| EBITDA | 2.88 | -1.15 | -0.24 | -6.10 | 14.49 | 11.28 | 11.33 | 9.45 | 19.11 |
| Non-Operating Income (Expense) | 3.65 | 2.25 | 5.92 | 55.30 | -0.55 | -0.79 | 0.09 | -0.13 | -0.21 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 11.05 | 11.03 | 7.72 | 8.32 | 8.81 | 7.81 | 6.62 | 5.54 | 6.75 |
| Price To Earnings Ratio | - | - | - | - | - | - | - | 7.97 | 11.71 |
| Price To Sales Ratio | 2.08 | 1.49 | 1.42 | 0.83 | 1.10 | 2.42 | 3.05 | 1.47 | 2.60 |
| Gross Margin | 52.34 | 51.29 | 50.39 | 46.61 | 45.89 | 46.26 | 47.65 | 50.03 | 51.34 |
| Operating Margin | -6.01 | -6.97 | -8.23 | -11.14 | -5.51 | -5.76 | -5.14 | -5.31 | -0.39 |
| Net Margin | -10.12 | -11.48 | -11.62 | -60.66 | -15.48 | -8.40 | -10.84 | -63.14 | 5.67 |
| Shares Outstanding | 42.42 | 41.70 | 40.99 | 40.43 | 39.61 | 39.17 | 38.55 | 38.08 | 37.61 |
| Market Capitalization | 522.32 | 522.32 | 414.19 | 252.74 | 371.18 | 761.25 | 881.74 | 384.87 | 699.29 |
Income statement, quarterly
| Metric | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 | 2024Q3 | 2024Q2 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 80.92 | 86.61 | 78.42 | 79.43 | 75.71 | 80.16 | 72.00 | 72.84 |
| Cost of Goods Sold Incl. D&A | 35.60 | 42.55 | 39.61 | 37.29 | 36.51 | 40.53 | 35.74 | 35.50 |
| Gross Profit | 45.31 | 44.05 | 38.81 | 42.14 | 39.20 | 39.63 | 36.26 | 37.34 |
| Selling, General and Administrative Excl. Other | 50.43 | 49.57 | 45.24 | 44.63 | 47.10 | 43.26 | 42.91 | 42.41 |
| Research and Development | 7.98 | 8.18 | 7.08 | 7.77 | 6.42 | 6.59 | 6.91 | 6.43 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -5.12 | -5.51 | -6.43 | -2.49 | -7.90 | -3.63 | -6.65 | -5.07 |
| Interest Expense | 0.09 | 0.10 | 0.09 | 0.10 | 0.00 | - | - | - |
| Unusual Expense | 2.18 | 4.13 | 6.52 | 3.63 | 2.76 | 2.15 | 3.33 | 6.02 |
| Net Income Before Taxes | -7.30 | -11.04 | -8.07 | -6.36 | -10.84 | -6.11 | -4.41 | -10.85 |
| Income Taxes | -0.20 | 0.37 | 0.01 | -0.01 | 0.07 | -0.06 | -0.00 | -0.11 |
| Consolidated Net Income | -7.10 | -11.40 | -8.08 | -6.35 | -10.90 | -6.05 | -4.41 | -10.74 |
| Net Income From Continuing Operations | -7.10 | -11.40 | -8.08 | -6.35 | -10.90 | -6.05 | -4.41 | -10.74 |
| Net Income | -7.10 | -11.40 | -8.08 | -6.35 | -10.90 | -6.05 | -4.41 | -10.74 |
| EPS (Recurring) | -0.13 | -0.20 | -0.08 | -0.09 | -0.22 | -0.11 | -0.05 | -0.16 |
| EPS (Basic, Before Extraordinaries) | -0.17 | -0.27 | -0.19 | -0.15 | -0.26 | -0.15 | -0.11 | -0.26 |
| EPS (Diluted) | -0.17 | -0.27 | -0.19 | -0.15 | -0.26 | -0.15 | -0.11 | -0.26 |
| EBITDA | 0.38 | 0.09 | -0.84 | 3.26 | -1.88 | 2.20 | -0.33 | 1.79 |
| Non-Operating Income (Expense) | 0.09 | -1.29 | 4.97 | -0.13 | -0.18 | -0.32 | 5.57 | 0.25 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 3.56 | 3.09 | 2.12 | 2.28 | 3.53 | 1.30 | 1.89 | 2.00 |
| Price To Sales Ratio | 2.08 | 1.50 | 1.52 | 1.68 | 1.40 | 1.43 | 1.34 | 0.99 |
| Gross Margin | 56.00 | 50.87 | 49.49 | 53.05 | 51.78 | 49.44 | 50.36 | 51.27 |
| Operating Margin | -6.33 | -6.36 | -8.20 | -3.13 | -10.43 | -4.53 | -9.23 | -6.96 |
| Net Margin | -8.77 | -13.17 | -10.31 | -7.99 | -14.40 | -7.55 | -6.12 | -14.74 |
| Shares Outstanding | 42.42 | 41.70 | 41.68 | 41.57 | 41.45 | 40.99 | 40.97 | 40.84 |
| Market Capitalization | 522.32 | 474.34 | 471.53 | 510.88 | 416.90 | 414.19 | 375.93 | 281.60 |
Balance sheet, annual
| Metric | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY | 2017FY |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 53.86 | 55.89 | 76.06 | 44.62 | 28.82 | 48.16 | 54.44 | 227.64 | 75.41 |
| Short Term Receivables | 48.51 | 42.89 | 43.61 | 52.83 | 56.50 | 37.32 | 31.26 | 43.58 | 39.40 |
| Inventories | 52.44 | 62.01 | 60.62 | 55.33 | 51.39 | 48.61 | 59.91 | 40.07 | 39.27 |
| Other Current Assets | 8.29 | 7.54 | 12.97 | 10.77 | 6.63 | 6.79 | 7.31 | 4.00 | 13.94 |
| Total Current Assets | 163.10 | 168.32 | 193.25 | 163.54 | 143.34 | 140.88 | 152.91 | 315.29 | 168.03 |
| Net Property, Plant & Equipment | 32.15 | 36.15 | 41.47 | 49.50 | 51.98 | 46.45 | 38.46 | 24.26 | 25.71 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 67.21 | 69.12 | 77.38 | 270.38 | 353.44 | 370.29 | 397.65 | 493.05 | 398.49 |
| Deferred Tax Assets | - | - | - | - | - | - | - | 0.32 | 0.08 |
| Other Assets | 4.70 | 6.55 | 5.57 | 49.22 | 3.99 | 3.81 | 5.19 | 3.52 | 113.15 |
| Total Assets | 267.16 | 280.14 | 317.67 | 532.64 | 552.75 | 561.44 | 594.21 | 836.44 | 705.47 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.70 | 1.84 | 1.98 | 1.92 | 2.56 | 2.42 | 2.08 | 7.50 | 5.00 |
| Accounts Payable | 31.51 | 33.29 | 37.75 | 40.45 | 28.05 | 19.63 | 19.10 | 22.83 | 15.78 |
| Other Current Liabilities | 41.51 | 41.07 | 51.43 | 41.46 | 43.72 | 35.54 | 30.27 | 42.97 | 36.53 |
| Total Current Liabilities | 74.72 | 76.20 | 91.16 | 83.83 | 74.32 | 57.58 | 51.45 | 73.30 | 57.30 |
| Long Term Debt | 9.26 | 2.11 | 3.94 | 53.13 | 29.70 | 27.32 | 48.34 | 124.41 | 86.62 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 5.32 | 4.07 | 4.85 | 12.81 | 16.04 | 19.95 | 24.06 | 14.54 | 17.17 |
| Other Liabilities | 7.04 | 14.80 | 12.14 | 4.57 | 8.20 | 17.12 | 15.49 | 9.37 | 1.78 |
| Total Liabilities | 96.34 | 97.17 | 112.08 | 154.34 | 128.26 | 121.98 | 139.34 | 221.62 | 162.88 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 170.82 | 182.97 | 205.59 | 378.30 | 424.49 | 439.46 | 454.87 | 614.82 | 542.60 |
| Total Shareholders Equity | 170.82 | 182.97 | 205.59 | 378.30 | 424.49 | 439.46 | 454.87 | 614.82 | 542.60 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 170.82 | 182.97 | 205.59 | 378.30 | 424.49 | 439.46 | 454.87 | 614.82 | 542.60 |
| Total Liabilities & Stockholders Equity | 267.16 | 280.14 | 317.67 | 532.64 | 552.75 | 561.44 | 594.21 | 836.44 | 705.47 |
| Book Value Per Share | 4.10 | 4.46 | 5.08 | 9.55 | 10.84 | 11.40 | 11.95 | 16.35 | 14.58 |
| Tangible Book Value Per Share | 2.48 | 2.78 | 3.17 | 2.72 | 1.81 | 1.79 | 1.50 | 3.24 | 3.87 |
| Full-Time Employees | 632 | 675 | 748 | 815 | 760 | 800 | 800 | 1,050 | 1,145 |
| Price to Book Ratio | 3.21 | 2.25 | 1.24 | 0.99 | 1.81 | 1.96 | 0.64 | 1.15 | 1.44 |
| Return on Assets | -13.43 | -11.37 | -43.36 | -9.66 | -4.77 | -5.46 | -23.32 | -1.45 | -0.88 |
| Return on Equity | -20.77 | -17.50 | -63.15 | -13.07 | -6.15 | -7.06 | -31.18 | -1.93 | -1.18 |
| Return on Invested Capital | -20.40 | -18.37 | -87.98 | -12.16 | -5.84 | -6.76 | -33.14 | 2.08 | 2.60 |
| Quick Ratio | 1.48 | 1.40 | 1.46 | 1.29 | 1.24 | 1.60 | 1.81 | 3.75 | 2.25 |
| Current Ratio | 2.18 | 2.21 | 2.12 | 1.95 | 1.93 | 2.45 | 2.97 | 4.30 | 2.93 |
Cash flow, annual
| Metric | TTM | 2025FY | 2024FY | 2023FY | 2022FY | 2021FY | 2020FY | 2019FY | 2018FY |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -32.94 | -36.74 | -33.99 | -184.35 | -52.44 | -26.55 | -31.55 | -166.79 | 61.34 |
| Depreciation | 22.43 | 22.95 | 25.80 | 27.71 | 33.36 | 31.79 | 28.37 | 25.88 | 25.88 |
| Other Funds (Non Cash) | 18.39 | 19.39 | 12.48 | 122.03 | 28.50 | 12.32 | 23.00 | 156.47 | -45.86 |
| Funds from Operations | 7.74 | 5.75 | 3.30 | -42.58 | 7.10 | 13.85 | 15.02 | 13.99 | 38.70 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -4.07 | -2.66 | -14.11 | 14.42 | -7.03 | -21.05 | 9.07 | -28.55 | -1.26 |
| Cash from Operating Activities | 3.67 | 3.09 | -10.81 | -28.16 | 0.08 | -7.19 | 24.09 | -14.55 | 37.44 |
| Capital Expenditures | -7.55 | -5.95 | -10.18 | -10.78 | -9.75 | -15.71 | -13.71 | -7.58 | -3.12 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.60 | 0.00 | -55.76 | -84.92 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 134.50 | 0.00 | 0.00 | 0.00 | 0.00 | 169.24 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.35 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.35 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -7.55 | -5.95 | -10.18 | 123.72 | -9.75 | -19.31 | -13.71 | -63.34 | 82.55 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -0.57 | 0.94 | -0.74 | 0.75 | 1.17 | 2.68 | 3.01 | -0.76 | 2.03 |
| Repurchase of Common Pref Stock | -1.28 | 0.00 | -1.67 | 0.00 | 0.00 | 0.00 | 0.00 | -0.76 | 0.00 |
| Sale of Common Pref Stock | 0.70 | 0.94 | 0.93 | 0.75 | 1.17 | 2.68 | 3.01 | 0.00 | 2.03 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | -0.38 | -0.38 | 0.00 | -50.00 | 24.25 | 5.00 | -20.00 | -93.28 | 40.00 |
| Change in Long Term Debt | -0.38 | -0.38 | 0.00 | -50.00 | 24.25 | 5.00 | -20.00 | -93.28 | 40.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 69.25 | 5.00 | 0.00 | 39.23 | 55.00 |
| Reduction of Long Term Debt | -0.38 | -0.38 | 0.00 | -50.00 | -45.00 | 0.00 | -20.00 | -132.50 | -15.00 |
| Net Financing Active Other Cash Flow | -0.01 | 0.00 | 1.16 | -15.00 | 0.00 | 0.00 | 0.00 | -1.21 | -8.10 |
| Other Financing Activities Uses | -0.01 | 0.00 | -5.15 | -15.00 | 0.00 | 0.00 | 0.00 | -1.21 | -8.10 |
| Cash from Financing Activities | -0.95 | 0.56 | 0.42 | -64.25 | 25.42 | 7.68 | -16.99 | -95.24 | 33.93 |
| Exchange Rate Effect | 0.04 | 0.27 | 0.40 | 0.12 | 0.04 | -0.52 | 0.33 | -0.07 | -0.38 |
| Net Change in Cash | -4.79 | -2.03 | -20.16 | 31.44 | 15.79 | -19.34 | -6.27 | -173.21 | 153.54 |
| Free Cash Flow | -3.87 | -2.86 | -20.99 | -35.69 | -9.13 | -22.90 | 10.38 | -21.79 | 34.32 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price to Free Cash Flow | - | - | - | - | - | - | 85.39 | - | 20.52 |
| Deferred Taxes & Investment Tax Credit | - | 0.14 | -0.99 | -7.97 | -2.31 | -3.71 | -4.80 | -1.57 | -2.65 |
Balance sheet, quarterly
| Metric | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 33.97 | 53.86 | 37.81 | 41.64 | 38.76 | 55.89 |
| Short Term Receivables | 44.91 | 48.51 | 45.55 | 44.43 | 42.64 | 42.89 |
| Inventories | 54.95 | 52.44 | 58.58 | 65.57 | 62.26 | 62.01 |
| Other Current Assets | 9.17 | 8.29 | 13.61 | 9.71 | 13.00 | 7.54 |
| Total Current Assets | 143.00 | 163.10 | 155.55 | 161.35 | 156.66 | 168.32 |
| Net Property, Plant & Equipment | 32.65 | 32.15 | 34.55 | 36.25 | 34.48 | 36.15 |
| Total Investments and Advances | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | 61.89 | 67.21 | 65.49 | 66.73 | 68.38 | 69.12 |
| Other Assets | 4.39 | 4.70 | 5.09 | 5.35 | 6.13 | 6.55 |
| Total Assets | 241.93 | 267.16 | 260.68 | 269.68 | 265.64 | 280.14 |
| Short Term Debt Incl. Current Port. of LT Debt | 1.80 | 1.70 | 1.71 | 1.71 | 2.17 | 1.84 |
| Accounts Payable | 26.58 | 31.51 | 29.11 | 35.39 | 31.88 | 33.29 |
| Other Current Liabilities | 31.31 | 41.51 | 35.25 | 34.86 | 34.23 | 41.07 |
| Total Current Liabilities | 59.69 | 74.72 | 66.07 | 71.96 | 68.28 | 76.20 |
| Long Term Debt | 8.94 | 9.26 | 9.68 | 10.08 | 7.42 | 2.11 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Tax Liabilities | 4.68 | 5.32 | 4.55 | 4.33 | 4.27 | 4.07 |
| Other Liabilities | 4.67 | 7.04 | 7.02 | 6.98 | 6.81 | 14.80 |
| Total Liabilities | 77.97 | 96.34 | 87.32 | 93.35 | 86.79 | 97.17 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 163.96 | 170.82 | 173.36 | 176.33 | 178.85 | 182.97 |
| Total Shareholders Equity | 163.96 | 170.82 | 173.36 | 176.33 | 178.85 | 182.97 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 163.96 | 170.82 | 173.36 | 176.33 | 178.85 | 182.97 |
| Total Liabilities & Stockholders Equity | 241.93 | 267.16 | 260.68 | 269.68 | 265.64 | 280.14 |
| Book Value Per Share | 3.86 | 4.10 | 4.16 | 4.24 | 4.32 | 4.46 |
| Tangible Book Value Per Share | 2.41 | 2.48 | 2.59 | 2.64 | 2.67 | 2.78 |
| Full-Time Employees | - | 632 | - | - | - | 675 |
| Price to Book Ratio | 3.21 | 2.76 | 2.70 | 2.87 | 2.30 | 2.25 |
| Return on Assets | -12.98 | -13.43 | -11.50 | -9.87 | -11.48 | -11.37 |
| Return on Equity | -19.21 | -20.77 | -17.47 | -15.26 | -17.10 | -17.50 |
| Return on Invested Capital | -4.10 | -6.33 | -4.42 | -3.41 | -5.85 | -3.27 |
| Quick Ratio | 1.48 | 1.48 | 1.47 | 1.33 | 1.38 | 1.40 |
| Current Ratio | 2.40 | 2.18 | 2.35 | 2.24 | 2.29 | 2.21 |
Cash flow, quarterly
| Metric | 2026Q1 | 2025Q4 | 2025Q3 | 2025Q2 | 2025Q1 | 2024Q4 |
|---|---|---|---|---|---|---|
| Net Income | -7.10 | -11.40 | -8.08 | -6.35 | -10.90 | -6.05 |
| Depreciation | 5.50 | 5.60 | 5.59 | 5.75 | 6.02 | 5.83 |
| Other Funds (Non Cash) | 4.26 | 6.60 | 3.78 | 3.75 | 5.26 | 1.81 |
| Funds from Operations | 2.35 | 0.95 | 1.34 | 3.10 | 0.36 | 1.40 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -17.68 | 16.51 | -4.45 | 1.56 | -16.27 | 16.73 |
| Cash from Operating Activities | -15.33 | 17.45 | -3.11 | 4.66 | -15.91 | 18.13 |
| Capital Expenditures | -3.15 | -1.27 | -1.51 | -1.62 | -1.55 | -2.62 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -3.15 | -1.27 | -1.51 | -1.62 | -1.55 | -2.62 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | -1.28 | -0.01 | 0.72 | 0.00 | 0.23 | 0.00 |
| Repurchase of Common Pref Stock | -1.28 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 0.00 | -0.01 | 0.72 | 0.00 | 0.23 | 0.00 |
| Proceedsfrom Stock Options | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance or Reduction of Debt, Net | 0.00 | -0.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | -0.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | -0.38 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.10 | 0.28 | -0.10 | -0.09 | -0.09 | -5.09 |
| Other Financing Activities Uses | -0.10 | 0.28 | -0.10 | -0.09 | -0.09 | -5.09 |
| Cash from Financing Activities | -1.38 | -0.11 | 0.62 | -0.09 | 0.14 | -5.09 |
| Exchange Rate Effect | -0.04 | -0.02 | 0.17 | -0.07 | 0.19 | 0.71 |
| Net Change in Cash | -19.89 | 16.05 | -3.83 | 2.88 | -17.13 | 11.13 |
| Free Cash Flow | -18.48 | 16.18 | -4.62 | 3.04 | -17.46 | 15.51 |
Revenue breakdown
| Med Device | 2024: 165.85M 2025: 170.22M |
|---|---|
| Med Tech | 2024: 126.65M 2025: 149.95M |
| Non-US | 2024: 41.52M 2025: 45.25M |
| United States | 2024: 250.98M 2025: 274.92M |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 5.38% | 2.0M | 37.2M | 640.46K |
| 2026-10-15 | 5.15% | 1.9M | 37.2M | 605.10K |
| 2026-09-30 | 3.48% | 1.3M | 37.2M | 478.67K |
| 2026-09-15 | 3.67% | 1.3M | 36.6M | 458.80K |
| 2026-08-31 | 3.73% | 1.4M | 36.6M | 440.77K |
| 2026-08-14 | 3.70% | 1.4M | 36.6M | 451.77K |
| 2026-07-31 | 3.34% | 1.2M | 36.6M | 408.23K |
| 2026-07-15 | 3.60% | 1.3M | 36.6M | 383.33K |
| 2026-06-30 | 3.71% | 1.4M | 36.6M | 396.33K |
| 2026-06-15 | 4.81% | 1.8M | 36.6M | 390.89K |
| 2026-05-29 | 5.17% | 1.9M | 36.6M | 391.73K |
| 2026-05-15 | 5.34% | 2.0M | 36.6M | 390.80K |
| 2026-04-30 | 5.67% | 2.1M | 36.5M | 422.33K |
| 2026-04-15 | 5.91% | 2.2M | 36.5M | 447.24K |
| 2026-03-31 | 4.98% | 1.8M | 36.5M | 551.20K |
| 2026-03-13 | 4.90% | 1.8M | 36.5M | 538.98K |
| 2026-02-27 | 5.97% | 2.2M | 36.5M | 557.71K |
| 2026-02-13 | 4.66% | 1.7M | 36.5M | 590.12K |
| 2026-01-30 | 5.31% | 2.1M | 38.9M | 587.79K |
| 2026-01-15 | 5.31% | 2.1M | 38.9M | 582.84K |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 8.70 | 11.10 | 9.05 | 14.044 | 0.00 | 0.00 | 0.964 | -0.109 | 0.002 |
| call | 5.00 | 6.20 | 9.20 | 0.00 | 9.900 | 0.00 | 0.00 | 0.915 | -0.123 | 0.003 |
| call | 7.50 | 2.65 | 6.10 | 0.00 | 5.119 | 0.00 | 0.00 | 0.856 | -0.115 | 0.004 |
| call | 10.00 | 1.50 | 2.60 | 1.63 | 1.323 | 63.00 | 0.00 | 0.763 | -0.095 | 0.006 |
| call | 12.50 | 0.00 | 1.40 | 0.18 | 1.861 | 26.00 | 1.00 | 0.576 | -0.113 | 0.008 |
| call | 15.00 | 0.00 | 0.95 | 0.05 | 2.340 | 81.00 | 0.00 | 0.369 | -0.097 | 0.007 |
| call | 17.50 | 0.00 | 2.15 | 0.05 | 1.752 | 27.00 | 0.00 | 0.132 | -0.041 | 0.004 |
| call | 20.00 | 0.00 | 0.95 | 0.00 | 2.199 | 0.00 | 0.00 | 0.111 | -0.046 | 0.004 |
| call | 22.50 | 0.00 | 0.95 | 0.00 | 2.569 | 0.00 | 0.00 | 0.100 | -0.049 | 0.003 |
| call | 25.00 | 0.00 | 0.95 | 0.00 | 2.886 | 0.00 | 0.00 | 0.092 | -0.052 | 0.003 |
| call | 30.00 | 0.00 | 0.95 | 0.00 | 3.408 | 0.00 | 0.00 | 0.081 | -0.056 | 0.003 |
| put | 2.50 | 0.00 | 0.95 | 0.00 | 12.524 | 0.00 | 0.00 | -0.036 | -0.108 | 0.002 |
| put | 5.00 | 0.00 | 0.95 | 0.00 | 7.217 | 0.00 | 0.00 | -0.085 | -0.123 | 0.003 |
| put | 7.50 | 0.00 | 0.95 | 0.00 | 4.620 | 0.00 | 0.00 | -0.144 | -0.114 | 0.004 |
| put | 10.00 | 0.00 | 0.95 | 0.00 | 2.802 | 0.00 | 0.00 | -0.237 | -0.094 | 0.006 |
| put | 12.50 | 0.00 | 2.70 | 0.00 | 3.492 | 0.00 | 0.00 | -0.424 | -0.112 | 0.008 |
| put | 15.00 | 0.90 | 4.80 | 3.50 | 4.031 | 1.00 | 0.00 | -0.631 | -0.095 | 0.007 |
| put | 17.50 | 3.30 | 7.10 | 6.34 | 4.530 | 0.00 | 0.00 | -0.868 | -0.039 | 0.004 |
| put | 20.00 | 6.70 | 9.10 | 0.00 | 4.448 | 0.00 | 0.00 | -0.889 | -0.044 | 0.004 |
| put | 22.50 | 9.30 | 11.40 | 0.00 | 4.640 | 0.00 | 0.00 | -0.900 | -0.047 | 0.003 |
| put | 25.00 | 10.80 | 14.30 | 0.00 | 5.608 | 0.00 | 0.00 | -0.908 | -0.049 | 0.003 |
| put | 30.00 | 16.60 | 18.90 | 0.00 | 5.689 | 0.00 | 0.00 | -0.919 | -0.053 | 0.003 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-11-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-11-04 | 3 | Initial statement of beneficial ownership of securities | 2026-11-02 | SEC |
| 2026-10-30 | 4 | Statement of changes in beneficial ownership of securities | 2026-10-28 | SEC |
| 2026-10-29 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-10-08 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-08-31 | SEC |
| 2026-10-08 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-10-08 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-11-17 | SEC |
| 2026-10-08 | 8-K | Current report | 2026-10-08 | SEC |
| 2026-10-08 | 8-K | Current report | 2026-10-02 | SEC |
| 2026-09-29 | 10-K/A | 2026-05-31 | SEC | |
| 2026-09-29 | 10-K/A | 2026-05-31 | SEC | |
| 2026-07-31 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-30 | SEC |
| 2026-07-30 | 144 | Filing for proposed sale of securities under Rule 144. | SEC | |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-22 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-22 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-22 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-22 | SEC |
| 2026-07-24 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-22 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
| 2026-07-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-07-15 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 310.69K | 2 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 344.01K | 1 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 0 | 0 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| BlackRock, Inc. | 9.20% |
| Point72 Asset Management, L.P. | 7.41% |
| SYSTEMATIC FINANCIAL MANAGEMENT LP | 6.39% |
| ARMISTICE CAPITAL, LLC | 5.32% |
| ROYCE & ASSOCIATES LP | 4.65% |
| Broadfin Holdings LLC | 4.40% |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.10% |
| WEBER CAPITAL MANAGEMENT LLC /ADV | 3.27% |
| GEODE CAPITAL MANAGEMENT, LLC | 2.45% |
| STATE STREET CORP | 2.32% |
Funds
| Fund | % owned |
|---|---|
| BlackRock Advantage Small Cap Core Fund | 0.55% |
| Adara Smaller Companies Fund | 0.35% |
| Avantis U.S. Small Cap Equity ETF | 0.22% |
| Goldman Sachs Small Cap Equity Insights Fund | 0.15% |
| Goldman Sachs ActiveBeta(R) U.S. Small Cap Equity ETF | 0.15% |
| Goldman Sachs Small Cap Value Insights Fund | 0.13% |
| Small Cap Index Fund | 0.05% |
| Virtus AlphaSimplex Global Alternatives Fund | 0.03% |
| iShares Russell 3000 ETF | 0.02% |
| Clearwater Select Equity Fund | 0.02% |
OakChart. ANGO. Cached 15 minutes.